Evreux, France and Kansas City, USA, October 31, 2017 — Citoxlab Group, a leading player among non-clinical CROs, announces today the acquisition of Xenometrics, an American CRO specialized in the non-clinical assessment of new drug candidates. This acquisition is the third one made by Citoxlab in North America further to the acquisition of the LAB Research Group (2011) and Accellab (2016). The financial terms of the agreement were not disclosed.

Xenometrics is a non-clinical CRO offering comprehensive services in the fields of safety, pharmacology and pharmacokinetics to customers from the pharmaceutical, biotechnology and chemical industries. With a staff of around 100 people, Xenometrics has built a robust scientific reputation since its creation almost 20 years ago. It is widely recognized as a flexible organization, which is key for an R&D service provider.

Through this acquisition, Citoxlab Group reinforces its position in the non-clinical CRO arena, with consolidated revenues of $148 million (€128M) and a staff of 1,200, spread over seven sites in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), Hungary (Veszprem), Denmark (Copenhagen), and now in the USA (Kansas City).

Dr. Jean-Francois Le Bigot, Chairman and CEO of Citoxlab Group said: "We were actively looking for an investment opportunity in the US as part of our growth strategy. This is important to better serve our US clients and I am very happy that we have identified the right opportunity with Xenometrics and successfully closed this acquisition. This CRO, created as a spin-off from a large pharma company, has tremendous non-clinical expertise and a strong reputation as a flexible organization capable of meeting the customers’ needs in project management during early development. This is really key, in particular for biotech companies that fight against time in order to reach milestones in their time-sensitive development plans. Two other criteria were also critical in our decision: - the staff is exceptionally stable, which results in experienced people who not only know their job, but also the specific requests or habits of their clients, - the location in Kansas City which is easy to reach for most American customers. For all these reasons, I am very confident and very excited that this acquisition will allow us to provide more services and additional capacity to our client portfolio with an increase in study slots.”

Dr. Alfred Botchway, PhD, DSP, one of the founders and the CEO of Xenometrics, said: “We are very proud that a leader like Citoxlab decided to invest in our company. We have been well aware of their excellent reputation as a science-driven CRO. In addition to this, I also realized that they have an impressive long-term development strategy, which is rare nowadays. We are very confident that joining the Citoxlab Group is a true opportunity for the future development of Xenometrics and its staff. We have already defined together several very concrete short and long term investments goals to improve and broaden our capabilities and services in Kansas City.”

About Xenometrics
Xenometrics LLC, is a US based GLP compliant, USDA registered, AAALAC accredited non-clinical contract laboratory that provides non-clinical research services to the pharmaceutical, biotechnology, veterinary and agro-chemical industry. Xenometrics performs studies in the field of toxicology, safety pharmacology and pharmacokinetics. Xenometrics has a staff of approximately 100 people, and located on a Bioscience Research Park located just south of downtown Kansas City.

For more information: http://www.xenometricsllc.com

Media and Analysts Contact
Agnes Stephens / Juliette dos Santos
Andrew Lloyd & Associates
UK: + 44 1273 675 100
US: + 1 617 202 4491
@ALA_Group